Trial Profile
Uncontrolled, Multicenter, Dose Finding, Safety and Pharmacokinetic Study of AVE1642, an Anti-Insulin-like Growth Factor-1 Receptor (IGF-IR/CD221) Monoclonal Antibody, Administered as Single Agent and in Combination with Anticancer Therapies in Patients with Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Jul 2019
Price :
$35
*
At a glance
- Drugs VRDN 001 (Primary) ; Docetaxel; Doxorubicin; Erlotinib; Gemcitabine
- Indications Solid tumours
- Focus Adverse reactions
- 27 Jul 2019 Status changed from suspended to completed.
- 10 Mar 2009 New trial record